Medpace (NASDAQ:MEDP – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Wednesday.
A number of other equities analysts have also recently commented on MEDP. Truist Financial initiated coverage on Medpace in a report on Thursday, August 1st. They issued a “hold” rating and a $415.00 target price on the stock. TD Cowen decreased their price objective on Medpace from $452.00 to $434.00 and set a “buy” rating on the stock in a research note on Wednesday, July 24th. Guggenheim cut their price objective on Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a report on Wednesday, July 24th. Finally, Robert W. Baird lowered their price target on shares of Medpace from $469.00 to $430.00 and set an “outperform” rating on the stock in a report on Wednesday, July 24th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Medpace presently has an average rating of “Moderate Buy” and a consensus price target of $423.00.
View Our Latest Stock Report on Medpace
Medpace Stock Up 1.9 %
Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings data on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The company had revenue of $528.10 million for the quarter, compared to the consensus estimate of $528.41 million. During the same quarter last year, the firm posted $1.93 earnings per share. The firm’s revenue was up 14.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Medpace will post 11.66 EPS for the current year.
Institutional Trading of Medpace
A number of institutional investors and hedge funds have recently bought and sold shares of MEDP. Newbridge Financial Services Group Inc. purchased a new position in shares of Medpace during the second quarter valued at about $163,000. Sanctuary Advisors LLC bought a new stake in Medpace in the 2nd quarter worth approximately $1,346,000. Clearbridge Investments LLC raised its holdings in shares of Medpace by 55.1% during the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock worth $166,343,000 after acquiring an additional 143,481 shares in the last quarter. Cetera Investment Advisers boosted its position in shares of Medpace by 2.3% during the 2nd quarter. Cetera Investment Advisers now owns 11,757 shares of the company’s stock valued at $4,842,000 after acquiring an additional 263 shares during the last quarter. Finally, Truist Financial Corp grew its holdings in shares of Medpace by 21.2% in the second quarter. Truist Financial Corp now owns 3,700 shares of the company’s stock valued at $1,524,000 after purchasing an additional 648 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.
About Medpace
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Recommended Stories
- Five stocks we like better than Medpace
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- How Much Can You Make in Stocks in One Month?
- Trading Halts Explained
- This Is the Top Large-Cap Stock Insiders Are Buying
- Health Care Stocks Explained: Why You Might Want to Invest
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.